SCHEMBL1769031

SCHEMBL1769031

CC(C)C[C@H](N)C(=O)NCC[C@H](N)C(=O)O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 1/20 0.59
ANPEP P15144 4/20 0.53
RNPEP Q9H4A4 3/20 0.53
DNPEP Q9ULA0 3/20 0.53
SLC1A3 P43003 4/20 0.47
SLC1A2 P43004 4/20 0.47
SLC1A1 P43005 3/20 0.44
DPP7 Q9UHL4 2/20 0.42
LARS1 Q9P2J5 1/20 0.42
NOD1 Q9Y239 1/20 0.40
GRM8 O00222 1/20 0.39
GRM6 O15303 1/20 0.39
GRIN2D O15399 1/20 0.39
GRIN3B O60391 1/20 0.39
GSR P00390 1/20 0.39
CYP1A2 P05177 1/20 0.39
GRIK1 P39086 1/20 0.39
GRM5 P41594 1/20 0.39
GRIA1 P42261 1/20 0.39
GRIA2 P42262 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1768387 1.00 SLC7A5 (0.59) SLC7A5ANPEPRNPEPDNPEPSLC1A3
SCHEMBL1769602 1.00 SLC7A5 (0.59) SLC7A5ANPEPRNPEPDNPEPSLC1A3
SCHEMBL1769033 1.00 SLC7A5 (0.59) SLC7A5ANPEPRNPEPDNPEPSLC1A3
SCHEMBL10928131 0.88 DPP7 (0.54) SLC7A5ANPEPRNPEPDNPEPSLC1A3
SCHEMBL1277891 0.87 ANPEP (0.68) SLC7A5ANPEPRNPEPDNPEPDPP7
SCHEMBL14067667 0.87 ANPEP (0.68) SLC7A5ANPEPRNPEPDNPEPDPP7
SCHEMBL1277892 0.87 ANPEP (0.68) SLC7A5ANPEPRNPEPDNPEPDPP7
Bromide SCHEMBL7305048 0.85 ANPEP (0.66) SLC7A5ANPEPRNPEPDNPEPDPP7
Hydrochloric Acid SCHEMBL1277930 0.85 ANPEP (0.66) SLC7A5ANPEPRNPEPDNPEPDPP7
SCHEMBL7780961 0.85 RNPEP (0.49) SLC7A5ANPEPRNPEPDNPEPSLC1A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102712676-B There is the peptidomimetic that the template of CCR10 antagonistic activity is fixing 波利弗尔股份公司 2016-10-26 CN disclosed
US-8754038-B2 Template-fixed peptidomimetics with CCR10 antagonistic activity POLYPHOR AG (CH) 2014-06-17 US disclosed
US-20120283168-A1 TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVITY POLYPHOR AG (CH) 2012-11-08 US disclosed
EP-2501715-A1 TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVTY Polyphor Ag (CH) 2012-09-26 EP disclosed
WO-2011060832-A1 TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVITY POLYPHOR AG (CH) 2011-05-26 WO disclosed
WO-2011060937-A1 TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVTY POLYPHOR AG (CH) 2011-05-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120283168-A1 TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVITY CCR10, CCR1, CCRL2 SLC7A5 1767/4885ANPEP 297/4885RNPEP 281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.